MONDAY, Oct. 28, 2024 -- Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic...
Vous n'êtes pas connecté
MONDAY, Sept. 9, 2024 -- Empagliflozin confers kidney-protective benefits for patients with acute myocardial infarction (MI) and an increased risk for heart failure, according to a study presented at the European Society of Cardiology Congress...
MONDAY, Oct. 28, 2024 -- Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic...
WEDNESDAY, Oct. 30, 2024 -- Machine learning can help identify individuals with diabetes at high risk for diabetic cardiomyopathy (DbCM), according to...
Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive...
MONDAY, Oct. 21, 2024 -- Treating hospitalized patients with bloodstream infections with antibiotics for seven days is noninferior to treating for 14...
WEDNESDAY, Oct. 23, 2024 -- Patients with psychiatric disorders have an increased rate of sudden cardiac death (SCD), according to a study published...
MONDAY, Nov. 4, 2024 -- Individuals with a history of upper respiratory infections (URI) have an increased risk for developing Meniere disease (MD),...
Diabetes drug canagliflozin benefits patients of all ages. While SGLT2 inhibitors are known to reduce the risk of heart and kidney problems in...
WEDNESDAY, Oct. 30, 2024 -- Hypertension is the most common cardiovascular disease (CVD) comorbidity seen among dialysis patients globally, according...
A study reveals that a low-salt fasting-mimicking diet slows kidney disease progression in animal models and shows protective effects in human...
THURSDAY, Oct. 24, 2024 -- Malnutrition is more likely among patients undergoing multiple orthopedic surgeries, according to a study presented at the...